Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Hirono, Iriuchishima"'
Autor:
Atsushi Isoda, Yuri Miyazawa, Tetsuya Ishikawa, Shuhei Kanaya, Keita Nakayama, Masahiro Mihara, Hirono Iriuchishima, Akio Saito, Morio Matsumoto, Morio Sawamura
Purpose Vitamin D is a fundamental mediator of skeletal metabolism, but also plays an important role in the pathophysiology of multiple myeloma (MM). Recent studies have shown an association between vitamin D deficiency and racial outcomes in MM pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16d9a3340ef6b8257137ddfef4874c9b
https://doi.org/10.21203/rs.3.rs-1621537/v1
https://doi.org/10.21203/rs.3.rs-1621537/v1
Autor:
Akihiko Yokohama, Takayuki Maruhashi, Kanae Iwahara, Hiroshi Handa, Reina Ishikawa, Keiko Yokote, Hirono Iriuchishima, Natsumi Nishimoto, Kozue Susa, Tomomi Sekigami
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 66:566-570
Autor:
Izuru Nagaoka, Yousuke Kitazume, Maemi Souma, Takayuki Maruhashi, Sayaka Takeuchi, Kozue Susa, Natsumi Nishimoto, Kana Tashiro, Kanae Iwahara, Keiko Yokote, Hirono Iriuchishima, Akihiko Yokohama, Reina Ishikawa, Tomomi Sekigami
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 65:782-792
Autor:
Kanae Iwahara, Takayuki Maruhashi, Akihiko Yokohama, Hiroshi Handa, Natsumi Nishimoto, Kozue Susa, Hirono Iriuchishima, Tomomi Sekigami, Reina Ishikawa
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 67:507-508
Autor:
Hirono Iriuchishima, Keiyo Takubo, Yoshitaka Miyakawa, Ayako Nakamura-Ishizu, Yoshiteru Miyauchi, Nobuyuki Fujita, Kana Miyamoto, Takeshi Miyamoto, Eiji Ikeda, Masahiro Kizaki, Yoshihisa Nojima, Toshio Suda
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e30557 (2012)
The interaction with bone marrow (BM) plays a crucial role in pathophysiological features of multiple myeloma (MM), including cell proliferation, chemoresistance, and bone lesion progression. To characterize the MM-BM interactions, we utilized an in
Externí odkaz:
https://doaj.org/article/136cbdb31e1b4d92a247dae635faa08a
Autor:
Tomomi Sekigami, Takuma Ishizaki, Takeki Mitsui, Natsumi Nishimoto, Takayuki Maruhashi, Kanae Iwahara, Hirono Iriuchishima, Kozue Susa, Akihiko Yokohama, Takeshi Kobayashi, Reina Ishikawa, Ken Sato, Norifumi Tsukamoto
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 64:655-659
Autor:
Manato, Sugisaki, Takuma, Ishizaki, Hirono, Iriuchishima, Hiroaki, Shimizu, Kunio, Yanagisawa, Yoshiyuki, Ogawa, Akihiko, Yokohama, Takayuki, Saitoh, Norifumi, Tsukamoto, Hiroshi, Handa
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 60(8)
A 32-year-old woman was diagnosed with autoimmune hemolytic anemia (AIHA) at 12 weeks of a pregnancy examination and followed up closely without treatment. At 40 weeks of gestation, she underwent emergency caesarean section because of premature ruptu
Autor:
Hirono Iriuchishima, Akihiko Yokohama, Shunsuke Takahashi, Akito Maeshima, Hirokazu Murakami, Takayuki Saitoh, Takuma Ishizaki, Norifumi Tsukamoto, Hiroshi Handa
Publikováno v:
Bioscience Reports
Renal impairment (RI) is a common complication of multiple myeloma (MM) that significantly affects treatment efficacy and mortality. However, no useful biomarkers for early detection of renal damage in MM exist. Reports indicate that activin A, a mul
Autor:
Makiko Takizawa, Norifumi Tsukamoto, Hirono Iriuchishima, Akihiko Yokohama, Hiromi Koiso, Hisashi Takei, Kayoko Murayama, Takuma Ishizaki, Hiroshi Handa, Hirokazu Murakami, Hiroaki Shimizu, Akio Saito, Morio Matsumoto, Takayuki Saitoh, Yuri Miyazawa, Nobuhiko Kobayashi, Tetsuya Ishikawa
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e194-e195
Autor:
Fumihiko Nakamura, Morio Matsumoto, Takayuki Saitoh, Kayoko Murayama, Go Yamamoto, Eiichi Nagura, Hiroshi Handa, Kazuyuki Shimizu, Shuji Ozaki, Hirono Iriuchishima, Yoshihisa Nojima, Hirokazu Murakami, Jun Konishi
Publikováno v:
Acta Haematologica. 135:113-121
We investigated the treatment and outcome of Japanese patients with primary plasma cell leukemia (pPCL) in the era of novel agents and analyzed the risk factors affecting survival. Among 3,318 patients with symptomatic multiple myeloma (MM), 38 patie